Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...

These actions could postpone NIH-funded clinical trials and create cash flow issues for domestic biotech companies.

As an organization founded with an SBIR NIH/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial ...

NIH announced it would limit indirect funding to 15% on Friday, but it is unclear how much money this will take from St. Jude ...